Ulcerative Colitis

New guidelines suggest patients with moderate to severe ulcerative colitis should be treated with infliximab, tofacitinib, and ustekinumab.

The most common reason IBS patients discontinue treatment is a loss of prescription drug coverage.

Dr. David Rubin discusses what IBD patients can do if they are asked to stop immunosuppressant treatment because of COVID-19.

David T. Rubin, MD, discusses some of the reccomendations for treating patients with IBD during the pandemic.

Patients who do not have the coronavirus should continue IBD therapies, including all scheduled infusions.

Some gastrointestinal symptoms could be exacerbated by contracting the novel coronavirus.

A new deep learning system identifies patients with endoscopic and histologic remission with more than 90% accuracy.

Azathioprine is linked to a slightly higher eGFR for patients with inflammatory bowel disease.

Investigators conduct the first ever treat-to-target study looking at ustekinumab maintenance therapy for Crohn’s disease patients.

Investigators identify several factors linked to early intestinal surgery for Crohn’s disease patients including smoking, BMI, and maximum bowel wall thickness.

A 28-day patient log of gastrointestinal symptoms, stool consistency, psychological distress, and extraintestinal pain ratings informs investigators on the significance of markers.

In a new study, investigators link inflammatory bowel disease with a number of negative maternal and placental outcomes.

A specific allele could help predict whether a patient will develop anti-drug antibodies to infliximab and adalimumab for patients with Crohn’s disease.

In a new study, investigators examine whether a low FODMAP diet could be beneficial for patients suffering from quiescent IBD.

The once-daily therapy has been previously approved for treatment of adults with difficult-to-treat rheumatoid arthritis or psoriatic arthritis.

In the last decade, investigators have put an emphasis on better disease monitoring for digestive diseases. The result has been better patient outcomes.

Millie Long, MD, MPH, FACG, associate professor of medicine at the University of North Carolina, Chapel Hill, discusses the exciting research she saw at ACG 2019.

Miguel Regueiro, MD and George Khoudari, MD, both of the Cleveland Clinic, discuss predictors of colectomies for IBD-patients.

William Sandborn, MD, chief of the division of gastroenterology at University of California, San Diego, shares updates from ACG 2019 in the field of gastroenterology.

Cash talks ACG 2019 highlights and shares the findings of a poster presentation on a new bowel preparation for colonoscopy.

During the ACG meeting, investigators tested a subcutaneous form of vedolizumab to treat ulcerative colitis.

Miguel Regueiro, MD, of the Cleveland Clinic, talks about some of the medications that treat ulcerative colitis and Crohn's disease at the annual ACG meeting.

With the recent FDA approval, ustekinumab could be the first choice to treat ulcerative colitis.

Millie Long, MD, MPH, FACG, associate professor of medicine at the University of North Carolina, Chapel Hill, shares takeaways from a poster presentation at ACG 2019 on the use of day care and infectious complications in children born to mothers with inflammatory bowel disease.

In a study presented at the ACG 2019 meeting, investigators discuss their groundbreaking work on inflammatory bowel disease.

In a pioneer study, investigators investigate if cannabis users had less incidence of pancreatic necrosis and/or pancreatic/peripancreatic fluid collections.

Investigators test a subcutaneous version of vedolizumab for different durations to treat ulcerative colitis.

Stephen B. Hanauer, MD, discusses areas of unmet need in gastroenterology and shares what news made a splash at ACG 2019.

Millie Long, MD, MPH, FACG, shares initial updates from the ongoing TARGET-IBD study.

Brooks Cash, MD, delivers his take on areas of unmet need within the gastroenterology field.